EPIGENOMICS AG ANNOUNCES CONTINUATION OF PHARMACEUTICAL BIOMARKER RESEARCH COLLABORATION

Epigenomics AG, a molecular diagnostics company developing tests based on DNA methylation, announced today that the company has entered into an agreement to continue a collaboration with AstraZeneca Ltd. to identify and analyse potential DNA methylation biomarker candidates for use in AstraZeneca's oncology programs.

The Houston Chronicle (http://www.chron.com/disp/story.mpl/conws/3866430.html)